- Home
- HUMAW vs IDYA Comparison
HUMAW vs IDYA Comparison
Compare HUMAW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMAW
- IDYA
- Stock Information
- Founded
- HUMAW 2004
- IDYA 2015
- Country
- HUMAW United States
- IDYA United States
- Employees
- HUMAW 220
- IDYA N/A
- Industry
- HUMAW Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- HUMAW Health Care
- IDYA Health Care
- Exchange
- HUMAW Nasdaq
- IDYA Nasdaq
- Market Cap
- HUMAW N/A
- IDYA 1.9B
- IPO Year
- HUMAW N/A
- IDYA 2019
- Fundamental
- Price
- HUMAW N/A
- IDYA $22.10
- Analyst Decision
- HUMAW
- IDYA Strong Buy
- Analyst Count
- HUMAW 0
- IDYA 13
- Target Price
- HUMAW N/A
- IDYA $53.42
- AVG Volume (30 Days)
- HUMAW 14.2K
- IDYA 1.0M
- Earning Date
- HUMAW 03-21-2025
- IDYA 08-05-2025
- Dividend Yield
- HUMAW N/A
- IDYA N/A
- EPS Growth
- HUMAW N/A
- IDYA N/A
- EPS
- HUMAW N/A
- IDYA N/A
- Revenue
- HUMAW N/A
- IDYA $7,000,000.00
- Revenue This Year
- HUMAW N/A
- IDYA $101.20
- Revenue Next Year
- HUMAW N/A
- IDYA $286.70
- P/E Ratio
- HUMAW N/A
- IDYA N/A
- Revenue Growth
- HUMAW N/A
- IDYA N/A
- 52 Week Low
- HUMAW $1.18
- IDYA $13.45
- 52 Week High
- HUMAW $1.34
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- HUMAW N/A
- IDYA 58.41
- Support Level
- HUMAW N/A
- IDYA $20.50
- Resistance Level
- HUMAW N/A
- IDYA $22.86
- Average True Range (ATR)
- HUMAW 0.00
- IDYA 0.95
- MACD
- HUMAW 0.00
- IDYA -0.13
- Stochastic Oscillator
- HUMAW 0.00
- IDYA 67.71
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.